RESUMO
Aim This study aimed to determine and compare the cytotoxicity of light-cured composite resin (Enlight light cure composite (Ormco, Glendora, California, USA)), light-cured acrylic resin (Orthocryl LC (Dentaurum, Ispringen, Germany)), and the self-cure acrylic (DPI RR cold cure acrylic (Dental Products of India, Bombay Burmah Trading Corporation Ltd., Mumbai, India)) material and to determine which component is best to be used for the purpose of nasal stent fabrication in the nasoalveolar molding (NAM) technique for cleft therapy. Methods Circular discs made from Enlight light cure composite, Orthocryl LC, and self-cure acrylic were submerged for 24 hours in gingival fibroblast media (three discs of each material) and control medium (three discs of each material) that were both contained in plates. After analyzing the optical densities of the plates, the cytotoxicity of the products was assessed by measuring cell viability using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The compiled data was analyzed using IBM SPSS Statistics for Windows, V. 23.0 (IBM Corp., Armonk, NY). The normality of the data was evaluated using the Shapiro-Wilk test. One-way analysis of variance (ANOVA) and pairwise comparison made with Tukey's honestly significant difference (HSD) post hoc test with a significance level (p) of 0.05 were considered. Results The percentage of cell viability was between 80% and 150%. A significant mean difference was noted in the cell viability between the three groups (p=0.009). High mean cell viability was seen in Orthocryl LC. However, there was no significant mean difference between Orthocryl LC and Enlight light cure composite material (p=0.854). Conclusion Both Orthocryl LC and Enlight light cure composite materials are less cytotoxic when compared to the self-cure acrylic resin material and can be used to fabricate the nasal stent component for infants with cleft defects, undergoing NAM procedure.
RESUMO
Background This study aimed to determine the antibacterial properties of orthodontic adhesive infused with stannous oxide nanoparticles (NPs) against Lactobacillus acidophilus and Streptococcus mutans bacteria, along with assessing the shear bond strength (SBS) of this composite when compared to conventional, non-infused composites. Methods A concentration of 1% w/w tin dioxide NPs (SnO2 NPs) was added to Transbond XT Orthodontic Adhesive. This modified composite material was used to prepare composite discs for the evaluation of its antibacterial properties against L. acidophilus bacteria and S. mutans bacteria using the biofilm inhibition test. To evaluate the SBS of this modified adhesive material, 50 extracted premolar teeth were collected and divided into two groups, with 25 teeth in each group (n = 25). Orthodontic stainless steel brackets were bonded to these extracted teeth using the modified composite. A comparative analysis of the SBS of the nano-infused composite group was then performed against that of the control group using an Instron universal testing machine. Results Growth inhibition zones were produced around the composite discs infused with SnO2 NPs for both bacterial strains. After performing the biofilm inhibition test, it can be inferred that the nano-infused composite is capable of inhibiting the bacterial count better than the control group. A statistically significant difference was observed between the two groups, with the SBS of the nano-infused composite being higher (16.89 MPa) than the non-infused composite adhesive (15.49 MPa). Conclusion The antibacterial activity of orthodontic composites modified with SnO2 NPs was significant compared with conventional composites. The control group showed less SBS when compared to the NP-infused composite, with a statistically significant difference in mean SBS values between both groups.
RESUMO
This systematic review aims to investigate the impact of platelet-rich plasma (PRP) in conjunction with bone grafting on bone volume outcomes in secondary alveolar bone grafting (SABG) procedures among alveolar cleft patients. An exhaustive search involving PubMed, Cochrane, and Google Scholar databases yielded 20 relevant titles, ultimately leading to the inclusion of four articles meeting all specified criteria. Based on the Cochrane risk of bias in systematic reviews (ROBIS) tool, the studies showed a high risk of bias. The primary outcome, bone volume assessment, was analyzed across these articles. While the Cochrane ROBIS tool deemed the included articles to have a high risk of bias, the comparison between PRP and Non-PRP groups did not reveal a significant difference in bone volume. Radiographic data illustrated an initial three-month period of bone resorption post-graft, regardless of PRP application, followed by a six-month phase of heightened bone density, particularly discernible in the PRP groups. To sum up, our findings indicate an absence of substantial bone density increase in cleft patients undergoing SABG with PRP augmentation. Nonetheless, there was a modest trend that suggests potential incremental bone density improvement with PRP usage, underscoring the need to conduct rigorously designed, randomized controlled trials (RCTs) with low bias to validate these observations.
